Brief: Sino Biopharmaceutical Says China's NMPA Accepts Clinical Trial Application For TQB3142 "BCL-XL Protac"
12/08/2025 11:42
Aug 12 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: CHINA'S NMPA ACCEPTS CLINICAL TRIAL APPLICATION FOR TQB3142 "BCL-XL PROTAC" Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit